{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:40:40Z","timestamp":1785526840781,"version":"3.56.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005405","name":"Ritsumeikan University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005405","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"DOI":"10.1208\/s12248-026-01274-3","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:54:51Z","timestamp":1782845691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["In vivo Predictive Dissolution Test Using Biorelevant Bicarbonate Buffer for High-dose Free Acid Drug"],"prefix":"10.1208","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1007-9783","authenticated-orcid":false,"given":"Yuki","family":"Tarumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5652-1786","authenticated-orcid":false,"given":"Kiyohiko","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"1274_CR1","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1023\/a:1016473601633","volume":"19","author":"LX Yu","year":"2002","unstructured":"Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res. 2002;19:921\u20135. https:\/\/doi.org\/10.1023\/a:1016473601633.","journal-title":"Pharm Res"},{"key":"1274_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1023\/A:1011984216775","volume":"15","author":"JB Dressman","year":"1998","unstructured":"Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res. 1998;15:11\u201322. https:\/\/doi.org\/10.1023\/A:1011984216775.","journal-title":"Pharm Res"},{"key":"1274_CR3","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1021\/mp1001203","volume":"7","author":"M McAllister","year":"2010","unstructured":"McAllister M. Dynamic dissolution: a step closer to predictive dissolution testing? Mol Pharm. 2010;7:1374\u201387. https:\/\/doi.org\/10.1021\/mp1001203.","journal-title":"Mol Pharm"},{"key":"1274_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1874126601004020002","volume":"4","author":"N Fotaki","year":"2010","unstructured":"Fotaki N, Vertzoni M. Biorelevant dissolution methods and their applications in in vitro- in vivo correlations for oral formulations~!2009-09-14~!2009-11-02~!2010-04-29~! Open Drug Deliv J. 2010;4:2\u201313. https:\/\/doi.org\/10.2174\/1874126601004020002.","journal-title":"Open Drug Deliv J"},{"key":"1274_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ejpb.2019.04.017","volume":"140","author":"P Berben","year":"2019","unstructured":"Berben P, Ashworth L, Beato S, Bevernage J, Bruel J-L, Butler J, et al. Biorelevant dissolution testing of a weak base: interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation. Eur J Pharm Biopharm. 2019;140:141\u20138. https:\/\/doi.org\/10.1016\/j.ejpb.2019.04.017.","journal-title":"Eur J Pharm Biopharm"},{"key":"1274_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1208\/s12248-010-9203-3","volume":"12","author":"S Klein","year":"2010","unstructured":"Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J. 2010;12:397\u2013406. https:\/\/doi.org\/10.1208\/s12248-010-9203-3.","journal-title":"AAPS J"},{"key":"1274_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/nrd1032","volume":"2","author":"H Van De Waterbeemd","year":"2003","unstructured":"Van De Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise. Nat Rev Drug Discov. 2003;2:192\u2013204. https:\/\/doi.org\/10.1038\/nrd1032.","journal-title":"Nat Rev Drug Discov"},{"key":"1274_CR8","doi-asserted-by":"crossref","unstructured":"C\u00e1mara-Martinez I, Blechar JA, Ruiz-Picazo A, Garcia-Arieta A, Calandria C, Merino-Sanjuan V, et al. Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen. International Journal of Pharmaceutics. Elsevier; 2022;614:121415.","DOI":"10.1016\/j.ijpharm.2021.121415"},{"key":"1274_CR9","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejps.2017.03.019","volume":"102","author":"A Pestieau","year":"2017","unstructured":"Pestieau A, Evrard B. In vitro biphasic dissolution tests and their suitability for establishing in vitro-in vivo correlations: a historical review. Eur J Pharm Sci. 2017;102:203\u201319. https:\/\/doi.org\/10.1016\/j.ejps.2017.03.019.","journal-title":"Eur J Pharm Sci"},{"key":"1274_CR10","doi-asserted-by":"crossref","unstructured":"Higashino H, Develin C, Higashino C, Lim T, Miezeiewski B, Strab R, et al. The impact of surface area per volume (SA\/V) ratio on drug transport from supersaturated solutions of ketoconazole. European Journal of Pharmaceutics and Biopharmaceutics. Elsevier; 2023;188:147\u201352.","DOI":"10.1016\/j.ejpb.2023.05.016"},{"key":"1274_CR11","doi-asserted-by":"publisher","unstructured":"Garner A. Gastroduodenal Alkaline Secretion and Its Pathophysiological Significance. In: Domschke W, Konturek SJ, editors. The Stomach. Berlin, Heidelberg: Springer Berlin Heidelberg; 1993. p. 83\u201391. https:\/\/doi.org\/10.1007\/978-3-642-78176-6_7.","DOI":"10.1007\/978-3-642-78176-6_7"},{"key":"1274_CR12","doi-asserted-by":"publisher","first-page":"G608","DOI":"10.1152\/ajpgi.1985.248.6.G608","volume":"248","author":"YF Shiau","year":"1985","unstructured":"Shiau YF, Fernandez P, Jackson MJ, McMonagle S. Mechanisms maintaining a low-pH microclimate in the intestine. Am J Physiol Gastrointest Liver Physiol. 1985;248:G608-17. https:\/\/doi.org\/10.1152\/ajpgi.1985.248.6.G608.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1274_CR13","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/0016-5085(92)90763-O","volume":"102","author":"SP Feitelberg","year":"1992","unstructured":"Feitelberg SP, Hogan DL, Koss MA, Isenberg JI. pH threshold for human duodenal bicarbonate secretion and diffusion of CO2. Gastroenterology. 1992;102:1252\u20138.","journal-title":"Gastroenterology"},{"key":"1274_CR14","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1021\/acs.molpharmaceut.8b00783","volume":"15","author":"J Al-Gousous","year":"2018","unstructured":"Al-Gousous J, Sun KX, McNamara DP, Hens B, Salehi N, Langguth P, et al. Mass transport analysis of the enhanced buffer capacity of the bicarbonate\u2013CO2 buffer in a phase-heterogenous system: physiological and pharmaceutical significance. Mol Pharm. 2018;15:5291\u2013301. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.8b00783.","journal-title":"Mol Pharm"},{"key":"1274_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.xphs.2024.10.025","volume":"114","author":"Y Tarumi","year":"2025","unstructured":"Tarumi Y, Sugano K. Dissolution profiles of high-dose salt-form drugs in bicarbonate buffer and phosphate buffer. J Pharm Sci. 2025;114:477\u201385. https:\/\/doi.org\/10.1016\/j.xphs.2024.10.025.","journal-title":"J Pharm Sci"},{"key":"1274_CR16","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1021\/mp100198q","volume":"7","author":"HM Fadda","year":"2010","unstructured":"Fadda HM, Sousa T, Carlsson AS, Abrahamsson B, Williams JG, Kumar D, et al. Drug solubility in luminal fluids from different regions of the small and large intestine of humans. Mol Pharm. 2010;7:1527\u201332. https:\/\/doi.org\/10.1021\/mp100198q.","journal-title":"Mol Pharm"},{"key":"1274_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ejps.2013.08.027","volume":"57","author":"P Augustijns","year":"2014","unstructured":"Augustijns P, Wuyts B, Hens B, Annaert P, Butler J, Brouwers J. A review of drug solubility in human intestinal fluids: implications for the prediction of oral absorption. Eur J Pharm Sci. 2014;57:322\u201332. https:\/\/doi.org\/10.1016\/j.ejps.2013.08.027.","journal-title":"Eur J Pharm Sci"},{"key":"1274_CR18","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","volume":"22","author":"C Schiller","year":"2005","unstructured":"Schiller C, Fr\u00f6hlich CP, Giessmann T, Siegmund W, M\u00f6nnikes H, Hosten N, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2005;22:971\u20139. https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02683.x.","journal-title":"Aliment Pharmacol Ther"},{"key":"1274_CR19","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1021\/mp500210c","volume":"11","author":"DM Mudie","year":"2014","unstructured":"Mudie DM, Amidon GL, Amidon GE, Murray K, Hoad CL, Pritchard SE, et al. Quantification of gastrointestinal liquid volumes and distribution following a 240 mL dose of water in the fasted state. Mol Pharm. 2014;11:3039\u201347. https:\/\/doi.org\/10.1021\/mp500210c.","journal-title":"Mol Pharm"},{"key":"1274_CR20","doi-asserted-by":"crossref","unstructured":"Gotch F, Nadell J, Edelman IS, others. Gastrointestinal water and electrolytes. IV. The equilibration of deuterium oxide (D 2 O) in gastrointestinal contents and the proportion of total body water (TBW) in the gastrointestinal tract. The Journal of Clinical Investigation. Am Soc Clin Investig; 1957;36:289\u201396.","DOI":"10.1172\/JCI103423"},{"key":"1274_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2010.11.049","author":"K Sugano","year":"2011","unstructured":"Sugano K. Fraction of a dose absorbed estimation for structurally diverse low solubility compounds. Int J Pharm. 2011. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.11.049.","journal-title":"Int J Pharm"},{"key":"1274_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ejps.2014.10.016","volume":"67","author":"A Maharaj","year":"2015","unstructured":"Maharaj A, Fotaki N, Edginton A. Parameterization of small intestinal water volume using PBPK modeling. Eur J Pharm Sci. 2015;67:55\u201364.","journal-title":"Eur J Pharm Sci"},{"key":"1274_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-019-2731-3","volume":"37","author":"C Litou","year":"2020","unstructured":"Litou C, Psachoulias D, Vertzoni M, Dressman J, Reppas C. Measuring pH and buffer capacity in fluids aspirated from the fasted upper gastrointestinal tract of healthy adults. Pharm Res. 2020;37:42. https:\/\/doi.org\/10.1007\/s11095-019-2731-3.","journal-title":"Pharm Res"},{"key":"1274_CR24","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1021\/mp100149j","volume":"7","author":"DM Mudie","year":"2010","unstructured":"Mudie DM, Amidon GL, Amidon GE. Physiological parameters for oral delivery and in vitro testing. Mol Pharm. 2010;7:1388\u2013405. https:\/\/doi.org\/10.1021\/mp100149j.","journal-title":"Mol Pharm"},{"key":"1274_CR25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.ejpb.2019.01.010","volume":"136","author":"M Hofmann","year":"2019","unstructured":"Hofmann M, Thieringer F, Nguyen MA, M\u00e5nsson W, Galle PR, Langguth P. A novel technique for intraduodenal administration of drug suspensions\/solutions with concurrent pH monitoring applied to ibuprofen formulations. Eur J Pharm Biopharm. 2019;136:192\u2013202. https:\/\/doi.org\/10.1016\/j.ejpb.2019.01.010.","journal-title":"Eur J Pharm Biopharm"},{"key":"1274_CR26","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1021\/acs.molpharmaceut.7b00426","volume":"14","author":"B Hens","year":"2017","unstructured":"Hens B, Tsume Y, Bermejo M, Paixao P, Koenigsknecht MJ, Baker JR, et al. Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs. Mol Pharmaceutics. 2017;14:4281\u201394. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00426.","journal-title":"Mol Pharmaceutics"},{"key":"1274_CR27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14227\/DT230316P6","volume":"23","author":"IE Shohin","year":"2016","unstructured":"Shohin IE, Grebenkin DY, Malashenko EA, Stanishevskii YM, Ramenskaya GV. A brief review of the FDA dissolution methods database. Dissolution Technol. 2016;23:6\u201310.","journal-title":"Dissolution Technol"},{"key":"1274_CR28","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1002\/jps.24460","volume":"104","author":"BJ Krieg","year":"2015","unstructured":"Krieg BJ, Taghavi SM, Amidon GL, Amidon GE. In vivo predictive dissolution: comparing the effect of bicarbonate and phosphate buffer on the dissolution of weak acids and weak bases. J Pharm Sci. 2015;104:2894\u2013904. https:\/\/doi.org\/10.1002\/jps.24460.","journal-title":"J Pharm Sci"},{"key":"1274_CR29","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1002\/jps.24108","volume":"103","author":"BJ Krieg","year":"2014","unstructured":"Krieg BJ, Taghavi SM, Amidon GL, Amidon GE. In vivo predictive dissolution: transport analysis of the CO2, bicarbonate in vivo buffer system. J Pharm Sci. 2014;103:3473\u201390. https:\/\/doi.org\/10.1002\/jps.24108.","journal-title":"J Pharm Sci"},{"key":"1274_CR30","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1021\/acs.molpharmaceut.9b00187","volume":"16","author":"J Al-Gousous","year":"2019","unstructured":"Al-Gousous J, Salehi N, Amidon GE, Ziff RM, Langguth P, Amidon GL. Mass transport analysis of bicarbonate buffer: effect of the CO2-H2CO3 hydration-dehydration kinetics in the fluid boundary layer and the apparent effective pKa controlling dissolution of acids and bases. Mol Pharm. 2019;16:2626\u201335. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00187.","journal-title":"Mol Pharm"},{"key":"1274_CR31","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s11095-024-03702-5","volume":"41","author":"F Claussen","year":"2024","unstructured":"Claussen F, Al-Gousous J, Salehi N, Garcia MA, Amidon GL, Langguth P. Solubility vs dissolution in physiological bicarbonate buffer. Pharm Res. 2024;41:937\u201345. https:\/\/doi.org\/10.1007\/s11095-024-03702-5.","journal-title":"Pharm Res"},{"key":"1274_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2020.02.009","author":"M Hofmann","year":"2020","unstructured":"Hofmann M, Garc\u00eda MA, Al-Gousous J, Ruiz-Picazo A, Thieringer F, Nguyen MA, et al. In vitro prediction of in vivo absorption of ibuprofen from suspensions through rational choice of dissolution conditions. Eur J Pharm Biopharm. 2020. https:\/\/doi.org\/10.1016\/j.ejpb.2020.02.009.","journal-title":"Eur J Pharm Biopharm"},{"key":"1274_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2021.09.009","author":"K Krollik","year":"2022","unstructured":"Krollik K, Lehmann A, Wagner C, Kaidas J, Kubas H, Weitschies W. The effect of buffer species on biorelevant dissolution and precipitation assays \u2013 comparison of phosphate and bicarbonate buffer. Eur J Pharm Biopharm. 2022. https:\/\/doi.org\/10.1016\/j.ejpb.2021.09.009.","journal-title":"Eur J Pharm Biopharm"},{"key":"1274_CR34","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1023\/A:1026147620304","volume":"20","author":"DP McNamara","year":"2003","unstructured":"McNamara DP, Whitney KM, Goss SL. Use of a physiologic bicarbonate buffer system for dissolution characterization of ionizable drugs. Pharm Res. 2003;20:1641\u20136. https:\/\/doi.org\/10.1023\/A:1026147620304.","journal-title":"Pharm Res"},{"key":"1274_CR35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1021\/mp800148u","volume":"6","author":"JJ Sheng","year":"2009","unstructured":"Sheng JJ, McNamara DP, Amidon GL. Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. Mol Pharm. 2009;6:29\u201339. https:\/\/doi.org\/10.1021\/mp800148u.","journal-title":"Mol Pharm"},{"key":"1274_CR36","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1021\/acs.molpharmaceut.4c00028","volume":"21","author":"H Yamamoto","year":"2024","unstructured":"Yamamoto H, Sugano K. Drug crystal precipitation in biorelevant bicarbonate buffer: a well-controlled comparative study with phosphate buffer. Mol Pharm. 2024;21:2854\u201364. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00028.","journal-title":"Mol Pharm"},{"key":"1274_CR37","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1021\/acs.molpharmaceut.4c00996","volume":"22","author":"H Yamamoto","year":"2025","unstructured":"Yamamoto H, Sugano K. Effect of pH and buffer capacity of physiological bicarbonate buffer on precipitation of drugs. Mol Pharm. 2025;22:1318\u201328. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.4c00996.","journal-title":"Mol Pharm"},{"key":"1274_CR38","doi-asserted-by":"publisher","DOI":"10.1023\/a:1026147620304","author":"DP McNamara","year":"2003","unstructured":"McNamara DP, Whitney KM, Goss SL. Use of a physiologic bicarbonate buffer system for dissolution characterization of ionizable drugs. Pharm Res. 2003. https:\/\/doi.org\/10.1023\/a:1026147620304.","journal-title":"Pharm Res"},{"key":"1274_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2009.08.003","author":"HM Fadda","year":"2009","unstructured":"Fadda HM, Merchant HA, Arafat BT, Basit AW. Physiological bicarbonate buffers: stabilisation and use as dissolution media for modified release systems. Int J Pharm. 2009. https:\/\/doi.org\/10.1016\/j.ijpharm.2009.08.003.","journal-title":"Int J Pharm"},{"key":"1274_CR40","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s11095-023-03508-x","volume":"40","author":"A Sakamoto","year":"2023","unstructured":"Sakamoto A, Sugano K. Dissolution profiles of poorly soluble drug salts in bicarbonate buffer. Pharm Res. 2023;40:989\u201398. https:\/\/doi.org\/10.1007\/s11095-023-03508-x.","journal-title":"Pharm Res"},{"key":"1274_CR41","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11095-024-03701-6","volume":"41","author":"N Okamoto","year":"2024","unstructured":"Okamoto N, Higashino M, Yamamoto H, Sugano K. Dissolution profiles of immediate release products of various drugs in biorelevant bicarbonate buffer: comparison with compendial phosphate buffer. Pharm Res. 2024;41:959\u201366. https:\/\/doi.org\/10.1007\/s11095-024-03701-6.","journal-title":"Pharm Res"},{"key":"1274_CR42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ejps.2015.06.015","volume":"77","author":"R Wulff","year":"2015","unstructured":"Wulff R, Rappen G-M, Koziolek M, Garbacz G, Leopold CS. Controlled release of acidic drugs in compendial and physiological hydrogen carbonate buffer from polymer blend-coated oral solid dosage forms. Eur J Pharm Sci. 2015;77:246\u201353.","journal-title":"Eur J Pharm Sci"},{"key":"1274_CR43","doi-asserted-by":"crossref","unstructured":"Liu F, Merchant HA, Kulkarni RP, Alkademi M, Basit AW. Evolution of a physiological pH 6.8 bicarbonate buffer system: application to the dissolution testing of enteric coated products. European Journal of Pharmaceutics and Biopharmaceutics. Elsevier; 2011;78:151\u20137.","DOI":"10.1016\/j.ejpb.2011.01.001"},{"key":"1274_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.06.031","author":"DA Silva","year":"2020","unstructured":"Silva DA, Davies NM, Doschak MR, Al-Gousous J, Bou-Chacra N, L\u00f6benberg R. Mechanistic understanding of underperforming enteric coated products: opportunities to add clinical relevance to the dissolution test. J Control Release. 2020. https:\/\/doi.org\/10.1016\/j.jconrel.2020.06.031.","journal-title":"J Control Release"},{"issue":"6","key":"1274_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1208\/s12249-022-02310-z","volume":"23","author":"D Haznar-Garbacz","year":"2022","unstructured":"Haznar-Garbacz D, Hoc D, Garbacz G, Lachman M, S\u0142omi\u0144ska D, Roma\u0144ski M. Dissolution of a Biopharmaceutics Classification System Class II free acid from immediate release tablets containing a microenvironmental pH modulator: comparison of a biorelevant bicarbonate buffering system with phosphate buffers. AAPS PharmSciTech. 2022;23:203. https:\/\/doi.org\/10.1208\/s12249-022-02310-z.","journal-title":"AAPS PharmSciTech"},{"key":"1274_CR46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s11095-025-03854-y","volume":"42","author":"Y Tarumi","year":"2025","unstructured":"Tarumi Y, Higashiguchi Y, Sugano K. Correlation between dissolution profiles of salt-form drugs in biorelevant bicarbonate buffer and oral drug absorption: importance of dose\/ fluid volume ratio. Pharm Res. 2025;42:623\u201337. https:\/\/doi.org\/10.1007\/s11095-025-03854-y.","journal-title":"Pharm Res"},{"key":"1274_CR47","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1002\/jps.24258","volume":"104","author":"D Dahlgren","year":"2015","unstructured":"Dahlgren D, Roos C, Sj\u00f6gren E, Lennern\u00e4s H. Direct in vivo human intestinal permeability (P eff) determined with different clinical perfusion and intubation methods. J Pharm Sci. 2015;104:2702\u201326. https:\/\/doi.org\/10.1002\/jps.24258.","journal-title":"J Pharm Sci"},{"key":"1274_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2015.01.014","volume":"480","author":"I Lozoya-Agullo","year":"2015","unstructured":"Lozoya-Agullo I, Zur M, Wolk O, Beig A, Gonz\u00e1lez-\u00c1lvarez I, Gonz\u00e1lez-\u00c1lvarez M, et al. In-situ intestinal rat perfusions for human Fabs prediction and BCS permeability class determination: investigation of the single-pass vs. the Doluisio experimental approaches. Int J Pharm. 2015;480:1\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2015.01.014.","journal-title":"Int J Pharm"},{"key":"1274_CR49","doi-asserted-by":"crossref","unstructured":"Gonzalez-Alvarez I, Ruiz-Picazo A, Selles-Talavera R, Figueroa-Campos A, Merino V, Bermejo M, et al. In Vivo Predictive Dissolution and Biopharmaceutic-Based In Silico Model to Explain Bioequivalence Results of Valsartan, a Biopharmaceutics Classification System Class IV Drug. Pharmaceutics. MDPI; 2024;16:390.","DOI":"10.3390\/pharmaceutics16030390"},{"key":"#cr-split#-1274_CR50.1","unstructured":"Novartis AG. Valsartan Drug Product Information. [cited 2025 Dec 31]"},{"key":"#cr-split#-1274_CR50.2","unstructured":"https:\/\/www.pro.novartis.com\/jp-ja\/sites\/pro_novartis_com_jp\/files\/2024-11\/if_dio_202305.pdf. Accessed 31 Dec 2025"},{"key":"1274_CR51","doi-asserted-by":"publisher","first-page":"268","DOI":"10.2165\/00003088-199732040-00002","volume":"32","author":"NM Davies","year":"1997","unstructured":"Davies NM, Anderson KE. <article-title update=\"added\">Clinical pharmacokinetics of naproxen: Clin Pharmacokinet. 1997;32:268\u201393. https:\/\/doi.org\/10.2165\/00003088-199732040-00002.","journal-title":"Clin Pharmacokinet"},{"key":"1274_CR52","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1023\/A:1011910801212","volume":"15","author":"E Galia","year":"1998","unstructured":"Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res. 1998;15:698\u2013705.","journal-title":"Pharm Res"},{"key":"1274_CR53","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1208\/s12248-009-9087-2","volume":"11","author":"SC Sutton","year":"2009","unstructured":"Sutton SC. Role of physiological intestinal water in oral absorption. The AAPS Journal. 2009;11:277\u201385.","journal-title":"The AAPS Journal"},{"key":"1274_CR54","doi-asserted-by":"publisher","DOI":"10.1002\/9781118354339","volume-title":"Biopharmaceutics Modeling and Simulations: theory, practice, methods, and applications","author":"K Sugano","year":"2012","unstructured":"Sugano K. Biopharmaceutics Modeling and Simulations: theory, practice, methods, and applications. John Wiley & Sons; 2012."},{"key":"1274_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/9781118286067","volume-title":"Absorption and Drug Development: Solubility, Permeability, and Charge State, Second Edition","author":"A Avdeef","year":"2012","unstructured":"Avdeef A. Absorption and Drug Development: Solubility, Permeability, and Charge State, Second Edition. John Wiley & Sons, Inc.; 2012."},{"key":"1274_CR56","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12272-011-0110-7","volume":"34","author":"J-S Song","year":"2011","unstructured":"Song J-S, Sohn Y-T. Crystal forms of naproxen. Arch Pharm Res. 2011;34:87\u201390. https:\/\/doi.org\/10.1007\/s12272-011-0110-7.","journal-title":"Arch Pharm Res"},{"key":"1274_CR57","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ijpharm.2017.04.067","volume":"526","author":"Y Guinet","year":"2017","unstructured":"Guinet Y, Paccou L, Dan\u00e8de F, Derollez P, H\u00e9doux A. Structural description of the marketed form of valsartan: a crystalline mesophase characterized by nanocrystals and conformational disorder. Int J Pharm. 2017;526:209\u201316.","journal-title":"Int J Pharm"},{"key":"1274_CR58","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1021\/cg400762w","volume":"13","author":"J-R Wang","year":"2013","unstructured":"Wang J-R, Wang X, Lu L, Mei X. Highly crystalline forms of valsartan with superior physicochemical stability. Cryst Growth Des. 2013;13:3261\u20139. https:\/\/doi.org\/10.1021\/cg400762w.","journal-title":"Cryst Growth Des"},{"key":"1274_CR59","doi-asserted-by":"crossref","unstructured":"Ono A, Matsumura N, Kimoto T, Akiyama Y, Funaki S, Tamura N, et al. Harmonizing solubility measurement to lower inter-laboratory variance\u2013progress of consortium of biopharmaceutical tools (CoBiTo) in Japan. ADMET and DMPK. Me{\\dj}unarodna udruga fizikalnih kemi\u010dara; 2019;7:183\u201395.","DOI":"10.5599\/admet.704"},{"key":"1274_CR60","doi-asserted-by":"publisher","first-page":"84","DOI":"10.5599\/admet.3.2.193","volume":"3","author":"A Avdeef","year":"2015","unstructured":"Avdeef A. Suggested improvements for measurement of equilibrium solubility-pH of ionizable drugs. ADMET DMPK. 2015;3:84\u2013109. https:\/\/doi.org\/10.5599\/admet.3.2.193.","journal-title":"ADMET DMPK"},{"key":"1274_CR61","doi-asserted-by":"publisher","DOI":"10.1002\/9781118286067","volume-title":"Absorption and Drug Development","author":"A Avdeef","year":"2012","unstructured":"Avdeef A. Absorption and Drug Development. Wiley Online Books; 2012."},{"key":"1274_CR62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/004982597240767","volume":"27","author":"F Waldmeier","year":"1997","unstructured":"Waldmeier F, Flesch G, Mu Ller P, Winkler T, Kriemler H-P, Buhlmayer P, et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica. 1997;27:59\u201371. https:\/\/doi.org\/10.1080\/004982597240767.","journal-title":"Xenobiotica"},{"key":"1274_CR63","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1002\/jps.21705","volume":"98","author":"AA Nomeir","year":"2009","unstructured":"Nomeir AA, Morrison R, Prelusky D, Korfmacher W, Broske L, Hesk D, et al. Estimation of the extent of oral absorption in animals from oral and intravenous pharmacokinetic data in drug discovery. J Pharm Sci. 2009;98:4027\u201338.","journal-title":"J Pharm Sci"},{"key":"1274_CR64","volume":"168","author":"T Uekusa","year":"2022","unstructured":"Uekusa T, Avdeef A, Sugano K. Is equilibrium slurry pH a good surrogate for solid surface pH during drug dissolution? European Journal of Pharmaceutical Sciences. Elsevier. 2022;168:106037.","journal-title":"Elsevier"},{"key":"1274_CR65","first-page":"454","volume":"3","author":"H Kalka","year":"2021","unstructured":"Kalka H. Polyprotic acids and beyond\u2014an algebraic approach. Chemistry (Basel). 2021;3:454\u2013508.","journal-title":"Chemistry (Basel)"},{"key":"1274_CR66","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090844","volume":"12","author":"N Matsumura","year":"2020","unstructured":"Matsumura N, Ono A, Akiyama Y, Fujita T, Sugano K. Bottom-up physiologically based oral absorption modeling of free weak base drugs. Pharmaceutics. 2020;12:844. https:\/\/doi.org\/10.3390\/pharmaceutics12090844.","journal-title":"Pharmaceutics"},{"key":"1274_CR67","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.xphs.2019.12.009","volume":"109","author":"N Matsumura","year":"2020","unstructured":"Matsumura N, Hayashi S, Akiyama Y, Ono A, Funaki S, Tamura N, et al. Prediction characteristics of oral absorption simulation software evaluated using structurally diverse low-solubility drugs. J Pharm Sci. 2020;109:1403\u201316. https:\/\/doi.org\/10.1016\/j.xphs.2019.12.009.","journal-title":"J Pharm Sci"},{"key":"1274_CR68","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1016\/j.xphs.2019.03.015","volume":"108","author":"Y Akiyama","year":"2019","unstructured":"Akiyama Y, Kimoto T, Mukumoto H, Miyake S, Ito S, Taniguchi T, et al. Prediction accuracy of mechanism-based oral absorption model for dogs. J Pharm Sci. 2019;108:2728\u201336.","journal-title":"J Pharm Sci"},{"key":"1274_CR69","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1273\/cbij.9.75","volume":"9","author":"K Sugano","year":"2009","unstructured":"Sugano K. Calculation of fraction of dose absorbed: comparison between analytical solution based on one compartment steady state concentration approximation and dynamic seven compartment model. Chem-Bio Inform J. 2009;9:75\u201393. https:\/\/doi.org\/10.1273\/cbij.9.75.","journal-title":"Chem-Bio Inform J"},{"key":"1274_CR70","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1023\/A:1018947113238","volume":"10","author":"D-M Oh","year":"1993","unstructured":"Oh D-M, Curl RL, Amidon GL. Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans: a mathematical model. Pharm Res. 1993;10:264\u201370.","journal-title":"Pharm Res"},{"key":"1274_CR71","doi-asserted-by":"publisher","DOI":"10.1080\/00498250701704819","author":"H Lennern\u00e4s","year":"2007","unstructured":"Lennern\u00e4s H. Intestinal permeability and its relevance for absorption and elimination. Xenobiotica. 2007. https:\/\/doi.org\/10.1080\/00498250701704819.","journal-title":"Xenobiotica"},{"key":"1274_CR72","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1098\/rsta.2010.0090","volume":"368","author":"Y Wang","year":"2010","unstructured":"Wang Y, Brasseur JG, Banco GG, Webb AG, Ailiani AC, Neuberger T. A multiscale lattice Boltzmann model of macro-to micro-scale transport, with applications to gut function. Philos Trans R Soc A Math Phys Eng Sci. 2010;368:2863\u201380. https:\/\/doi.org\/10.1098\/rsta.2010.0090.","journal-title":"Philos Trans R Soc A Math Phys Eng Sci"},{"key":"1274_CR73","doi-asserted-by":"publisher","first-page":"G922","DOI":"10.1152\/ajpgi.2001.280.5.g922","volume":"280","author":"C Atuma","year":"2017","unstructured":"Atuma C, Strugala V, Allen A, Holm L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol. 2017;280:G922-9. https:\/\/doi.org\/10.1152\/ajpgi.2001.280.5.g922.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1274_CR74","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1469-7793.1999.0507t.x","volume":"517","author":"AK Genz","year":"1999","unstructured":"Genz AK, Engelhardt WV, Busche R. Maintenance and regulation of the pH microclimate at the luminal surface of the distal colon of guinea-pig. J Physiol. 1999;517:507\u201319. https:\/\/doi.org\/10.1111\/j.1469-7793.1999.0507t.x.","journal-title":"J Physiol"},{"key":"1274_CR75","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF00588693","volume":"385","author":"ML Lucas","year":"1980","unstructured":"Lucas ML, Lei FH, Blair JA. The influence of buffer pH, glucose and sodium ion concentration on the acid microclimate in rat proximal jejunum in vitro. Pflugers Arch Eur J Physiol. 1980;385:137\u201342. https:\/\/doi.org\/10.1007\/BF00588693.","journal-title":"Pflugers Arch Eur J Physiol"},{"key":"1274_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102447","volume":"63","author":"A Sakamoto","year":"2021","unstructured":"Sakamoto A, Izutsu K, Yoshida H, Abe Y, Inoue D, Sugano K. Simple bicarbonate buffer system for dissolution testing: floating lid method and its application to colonic drug delivery system. J Drug Deliv Sci Technol. 2021;63:102447. https:\/\/doi.org\/10.1016\/j.jddst.2021.102447.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1274_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2022.106326","volume":"180","author":"S Ikuta","year":"2023","unstructured":"Ikuta S, Nakagawa H, Kai T, Sugano K. Development of bicarbonate buffer flow-through cell dissolution test and its application in prediction of in vivo performance of colon targeting tablets. Eur J Pharm Sci. 2023;180:106326. https:\/\/doi.org\/10.1016\/j.ejps.2022.106326.","journal-title":"Eur J Pharm Sci"},{"key":"1274_CR78","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1248\/cpb.c23-00783","volume":"72","author":"M Higashino","year":"2024","unstructured":"Higashino M, Sugano K. Dissolution profiles of oral disintegrating tablet with taste masking granule polymer coating in biorelevant bicarbonate buffer. Chem Pharm Bull Tokyo. 2024;72:298\u2013302. https:\/\/doi.org\/10.1248\/cpb.c23-00783.","journal-title":"Chem Pharm Bull Tokyo"},{"key":"1274_CR79","doi-asserted-by":"crossref","unstructured":"Fushimi M, Higashino M, Ikuta S, Yoshida H, Sugano K. Bicarbonate Buffer Dissolution Test Using the Floating Lid Method: Inter-Laboratory Reproducibility of pH Maintenance. 2025;73.","DOI":"10.1248\/cpb.c25-00283"},{"key":"1274_CR80","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.xphs.2024.08.013","volume":"114","author":"P Bapat","year":"2025","unstructured":"Bapat P, Schwabe R, Paul S, Tseng Y-C, Bergman C, Taylor LS. Exploring biorelevant conditions and release profiles of ritonavir from HPMCAS-based amorphous solid dispersions. J Pharm Sci. 2025;114:185\u201398.","journal-title":"J Pharm Sci"},{"key":"1274_CR81","doi-asserted-by":"crossref","unstructured":"Valapil RR, Polli JE. Impact of antioxidant addition on drug dissolution: Implications for NDSRI mitigation biowaivers. International Journal of Pharmaceutics. Elsevier; 2025;125806.","DOI":"10.1016\/j.ijpharm.2025.125806"},{"key":"1274_CR82","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.59.10.0007","author":"JE Boni","year":"2010","unstructured":"Boni JE, Brickl RS, Dressman J. Is bicarbonate buffer suitable as a dissolution medium. J Pharm Pharmacol. 2010. https:\/\/doi.org\/10.1211\/jpp.59.10.0007.","journal-title":"J Pharm Pharmacol"},{"key":"1274_CR83","doi-asserted-by":"publisher","first-page":"3938","DOI":"10.1021\/acs.molpharmaceut.9b00534","volume":"16","author":"C Jede","year":"2019","unstructured":"Jede C, Wagner C, Kubas H, Weigandt M, Weber C, Lecomte M, et al. Improved prediction of in vivo supersaturation and precipitation of poorly soluble weakly basic drugs using a biorelevant bicarbonate buffer in a gastrointestinal transfer model. Mol Pharm. 2019;16:3938\u201347. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.9b00534.","journal-title":"Mol Pharm"},{"key":"1274_CR84","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.addr.2007.05.008","volume":"59","author":"A Avdeef","year":"2007","unstructured":"Avdeef A. Solubility of sparingly-soluble ionizable drugs. Adv Drug Deliv Rev. 2007;59:568\u201390. https:\/\/doi.org\/10.1016\/j.addr.2007.05.008.","journal-title":"Adv Drug Deliv Rev"},{"key":"1274_CR85","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Dengra B, Ruiz-Picazo A, Gonzalez-Alvarez I, Gonzalez-Alvarez M, Bermejo M. In vitro two stage one compartment dumping test data and absorption\/formulation PBBM modeling to explain a bioequivalence failure of valsartan formulations. Eur J Pharm Biopharm. Elsevier; 2025;114932.","DOI":"10.1016\/j.ejpb.2025.114932"},{"key":"1274_CR86","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1021\/mp500152y","volume":"11","author":"M Zur","year":"2014","unstructured":"Zur M, Gasparini M, Wolk O, Amidon GL, Dahan A. The low\/high BCS permeability class boundary: physicochemical comparison of metoprolol and labetalol. Mol Pharm. 2014;11:1707\u201314. https:\/\/doi.org\/10.1021\/mp500152y.","journal-title":"Mol Pharm"},{"key":"1274_CR87","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/bdd.2510160502","volume":"16","author":"TT Kararli","year":"1995","unstructured":"Kararli TT. Comparison of the gastrointestinal anatomy, physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos. 1995;16:351\u201380. https:\/\/doi.org\/10.1002\/bdd.2510160502.","journal-title":"Biopharm Drug Dispos"},{"key":"1274_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2009.02.002","author":"K Sugano","year":"2009","unstructured":"Sugano K. Theoretical investigation of passive intestinal membrane permeability using Monte Carlo method to generate drug-like molecule population. Int J Pharm. 2009. https:\/\/doi.org\/10.1016\/j.ijpharm.2009.02.002.","journal-title":"Int J Pharm"},{"key":"1274_CR89","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11095-022-03173-6","volume":"40","author":"Y Akiyama","year":"2023","unstructured":"Akiyama Y, Matsumura N, Ono A, Hayashi S, Funaki S, Tamura N, et al. Prediction of oral drug absorption in rats from in vitro data. Pharm Res. 2023;40:359\u201373. https:\/\/doi.org\/10.1007\/s11095-022-03173-6.","journal-title":"Pharm Res"},{"key":"1274_CR90","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s002280050259","volume":"52","author":"G Flesch","year":"1997","unstructured":"Flesch G, M\u00fcller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 1997;52:115\u201320. https:\/\/doi.org\/10.1007\/s002280050259.","journal-title":"Eur J Clin Pharmacol"},{"key":"1274_CR91","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1023\/A:1016068705255","volume":"13","author":"KC Johnson","year":"1996","unstructured":"Johnson KC, Swindell AC. Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res. 1996;13:1795\u20138. https:\/\/doi.org\/10.1023\/A:1016068705255.","journal-title":"Pharm Res"},{"key":"1274_CR92","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1208\/s12248-025-01125-7","volume":"27","author":"K Sagawa","year":"2025","unstructured":"Sagawa K, Thipsay P. Commentary and review on prospective prediction of bioequivalence of oral dosage forms using compendial dissolution testing and PBPK modeling. AAPS J. 2025;27:136. https:\/\/doi.org\/10.1208\/s12248-025-01125-7.","journal-title":"AAPS J"},{"key":"1274_CR93","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/03639045.2025.2515999","volume":"51","author":"C Bai","year":"2025","unstructured":"Bai C, Zhang J, Xu X, Li X, Zhang T. Establishing virtual bioequivalence and bio-related dissolution specifications for naproxen using physiologically based pharmacokinetic modeling and in vitro biorelevant dissolution testing. Drug Dev Ind Pharm. 2025;51:895\u2013906. https:\/\/doi.org\/10.1080\/03639045.2025.2515999.","journal-title":"Drug Dev Ind Pharm"},{"key":"1274_CR94","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3870\/j.issn.1004-0781.2019.07.014","volume":"38","author":"W Tang","year":"2019","unstructured":"Tang W, Yin J, Zhang Y, Shi B, Li P, Lu Y, et al. Evaluation the Dissolution Curve Similarity of Naproxen Tablets and Study on the in Vitro-in Vivo Correlation Model. HERALD OF MEDICINE Herald of Medicine. 2019;38:899\u2013905. https:\/\/doi.org\/10.3870\/j.issn.1004-0781.2019.07.014.","journal-title":"HERALD OF MEDICINE Herald of Medicine"},{"key":"1274_CR95","doi-asserted-by":"crossref","unstructured":"Loisios-Konstantinidis I, Cristofoletti R, Fotaki N, Turner DB, Dressman J. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen. Eur J Pharm Sci. Elsevier; 2020;143:105170.","DOI":"10.1016\/j.ejps.2019.105170"},{"key":"1274_CR96","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-0162-4","author":"R Takano","year":"2006","unstructured":"Takano R, Sugano K, Higashida A, Hayashi Y, Machida M, Aso Y, et al. Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm Res. 2006. https:\/\/doi.org\/10.1007\/s11095-006-0162-4.","journal-title":"Pharm Res"},{"key":"1274_CR97","doi-asserted-by":"crossref","unstructured":"Pepin XJ, Sanderson NJ, Blanazs A, Grover S, Ingallinera TG, Mann JC. Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part I. Mechanistic modelling of drug product dissolution to derive a P-PSD for PBPK model input. Eur J Pharm Biopharm. Elsevier; 2019;142:421\u201334.","DOI":"10.1016\/j.ejpb.2019.07.014"},{"key":"1274_CR98","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev.nu.16.070196.000531","volume":"16","author":"FH Leibach","year":"1996","unstructured":"Leibach FH, Ganapathy V. Peptide transporters in the intestine and the kidney. Annu Rev Nutr. 1996;16:99\u2013119. https:\/\/doi.org\/10.1146\/annurev.nu.16.070196.000531.","journal-title":"Annu Rev Nutr"},{"key":"1274_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3187","author":"K Sugano","year":"2010","unstructured":"Sugano K, Kansy M, Artursson P, Avdeef A, Bendels S, Di L, et al. Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov. 2010. https:\/\/doi.org\/10.1038\/nrd3187.","journal-title":"Nat Rev Drug Discov"},{"key":"1274_CR100","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.addr.2011.07.007","volume":"64","author":"I Tamai","year":"2012","unstructured":"Tamai I. Oral drug delivery utilizing intestinal OATP transporters. Adv Drug Deliv Rev. 2012;64:508\u201314.","journal-title":"Adv Drug Deliv Rev"},{"key":"1274_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2014.09.010","author":"M Higuchi","year":"2014","unstructured":"Higuchi M, Yoshihashi Y, Tarada K, Sugano K. Minimum rotation speed to prevent coning phenomena in compendium paddle dissolution apparatus. Eur J Pharm Sci. 2014. https:\/\/doi.org\/10.1016\/j.ejps.2014.09.010.","journal-title":"Eur J Pharm Sci"},{"key":"1274_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2009.12.014","author":"K Sugano","year":"2010","unstructured":"Sugano K. Possible reduction of effective thickness of intestinal unstirred water layer by particle drifting effect. Int J Pharm. 2010. https:\/\/doi.org\/10.1016\/j.ijpharm.2009.12.014.","journal-title":"Int J Pharm"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01274-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-026-01274-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-026-01274-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:05:52Z","timestamp":1785521152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-026-01274-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":103,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1208\/s12248-026-01274-3","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kiyohiko Sugano is the founder of BioavailabilityDesign LLC.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"120"}}